Neonmind’s NEO-002 synthetic psilocybin candidate are going to be examined to be a very low-dose remedy to regulate and suppress individual urge for food. The corporate has secured pharmaceutical grade synthetic psilocybin from Psygen and anticipates initiating a Stage I/II evidence-of-strategy research for NEO-001 from the close to long https://irvingr531kjf1.wikibriefing.com/user